---
title: "GenFleet Tightens Board Nomination Rules to Strengthen Governance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280405534.md"
description: "GenFleet Therapeutics has updated its Board Nomination Committee terms to enhance governance, effective March 24, 2026. The committee, primarily composed of independent non-executive directors, will oversee board structure, succession planning, and diversity policy. Responsibilities include annual reviews of board size and skills, director selection criteria, and performance assessments. The committee can seek independent advice, aiming for transparent oversight and alignment with corporate governance standards in Hong Kong. GenFleet, a biopharmaceutical company listed in Hong Kong, focuses on innovative therapeutics and adheres to local listing rules and corporate law."
datetime: "2026-03-25T00:09:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280405534.md)
  - [en](https://longbridge.com/en/news/280405534.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280405534.md)
---

# GenFleet Tightens Board Nomination Rules to Strengthen Governance

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

An update from Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) is now available.

GenFleet Therapeutics has revised and adopted updated terms of reference for its Board Nomination Committee, effective 24 March 2026, to better regulate the appointment of directors and senior management and optimize board composition. The Nomination Committee, composed mainly of independent non-executive directors and including at least one director of a different gender, is tasked with overseeing board structure, succession planning, independence assessments and diversity policy, with its recommendations submitted to the full Board, underscoring the company’s focus on strengthened governance and regulatory compliance.

The committee’s responsibilities now explicitly cover annual reviews of board size and skills, formulation of director selection criteria and procedures, evaluation of directors’ time commitments and contributions, and support for regular board performance assessments. It is also empowered to seek independent professional advice at the company’s expense, signaling a move toward more rigorous, transparent oversight that could bolster investor confidence and align the company more closely with evolving corporate governance standards in Hong Kong’s capital markets.

**More about Genfleet Therapeutics (Shanghai), Inc. Class H**

GenFleet Therapeutics (Shanghai), Inc. is a China-based biopharmaceutical company listed in Hong Kong that operates in the life sciences sector. The company focuses on innovative therapeutics and relies on a formal board and committee structure to oversee the nomination and appointment of directors and senior management in line with Hong Kong listing rules and Chinese corporate law.

**Average Trading Volume:** 1,619,374

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** HK$10.31B

Learn more about 2595 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [02595.HK](https://longbridge.com/en/quote/02595.HK.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)

## Related News & Research

- [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)
- [Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds](https://longbridge.com/en/news/286487023.md)
- [Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities | DTCFF Stock News](https://longbridge.com/en/news/286870222.md)